Use of proton pump inhibitors (PPIs) appears to increase the risk of COVID-19 infection, according to findings of a US study published in the *American Journal of Gastroenterology*.

Multivariate regression analysis of data from a nationwide online survey conducted between May and June 2020, during the COVID-19 pandemic, was used to evaluate the association between PPI use and positive COVID-19 test results in 53 130 community-dwelling US adults under 60 years of age with gastrointestinal symptoms.

A positive COVID-19 test was reported in 6.4% of survey participants overall. The odds of a positive COVID-19 test was significantly increased in patients receiving once-daily PPI treatment (adjusted odds ratio \[aOR\] 2.15; 95% CI 1.90, 2.44) or twice-daily PPI treatment (aOR 3.67; 95% CI 2.93, 4.60) compared with patients receiving no PPI therapy.

The risk of COVID-19 infection was not significantly increased in patients receiving histamine H2-receptor antagonists.

\"We found evidence of an independent, dose-response relationship between the use of anti-secretory medications and COVI-19 positivity,\"concluded the authors. \"Our findings support good clinical practice that PPIs should only be used when indicated at the lowest effective dose, such as the approved once-daily label dosage of over-the-counter and prescription PPIs,\" they said.
